Kissei Pharmaceutical Co., Ltd.
KSPHF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -21.11 | 0.19 | -1.01 | 0.05 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 5,666.58 | 41.71 | 48.03 | 43.41 |
| Quality | ||||
| ROIC | -3.58% | 0.73% | 0.52% | 0.87% |
| Gross Margin | 49.10% | 49.93% | 48.31% | 50.51% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 409.92% | 459.28% | 462.27% | 449.27% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -7.14 | -8.44 | -8.88 | -4.94 |
| Interest Coverage | -1,278.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.44 | 0.47 | 0.43 |
| Cash Conversion Cycle | 29,086.00 | 268.81 | 274.33 | 294.87 |